StreetInsider.com News Articles

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

The analyst comments "Stock overcorrected on perception of 'F4 data coming late or coming delayed' (but a delay could be a long-term positive). Q2 beat also confirmed net-zero volume impact from Novo, setting up for consecutive revisions 2026-2027. Upgrading MDGL to OP."

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays

Mon, 03 Aug 2026 06:40:33 -0400

Barclays analyst Eliana Merle lowered the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $962.00 (from $964.00) while maintaining a Overweight rating.

Madrigal Pharma (MDGL) Tops Q2 EPS by 76c

Fri, 31 Jul 2026 09:18:28 -0400

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($1.99), $0.76 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $364.3 million versus the consensus estimate of $349.15 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Fri, 31 Jul 2026 06:42:01 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $620.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst commented: "Rezdiffra is now nine quarters into its commercial launch and continues to generate impressive growth, with 2Q26 net sales of $364.3M, up 71% YoY. Importantly, the F2–F3 addressable population continues to expand, growing nearly 50% over two years to approximately 460K patients by YE25. We continue to view this as a massively underpenetrated opportunity, with only approximately 10% of MASH patients diagnosed and Rezdiffra reaching only approximately 10% of the currently addressable population, according to our estimates. Ultimately, we believe

Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays

Fri, 31 Jul 2026 06:12:38 -0400

Barclays analyst Eliana Merle lowered the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $962.00 (from $964.00) while maintaining a Overweight rating.

The analyst comments "We think this was a strong Q, many inbounds as to why the stock was weak. F4c data expected in '27 a major catalyst where importantly we think slower event rates could be a good sign. We have conviction in shares at these levels and remain bullish on Rezdiffra and the MASH opportunity."

Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays

Fri, 31 Jul 2026 06:12:38 -0400

Barclays analyst Eliana Merle lowered the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $962.00 (from $964.00) while maintaining a Overweight rating.

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates